Prognostic stratification of patients with mitral regurgitation using artificial intelligence-enhanced electrocardiogram for left ventricular diastolic function assessment
Abstract Background The determination of left ventricular diastolic dysfunction (LVDD) and filling pressure in patients with significant (>moderate) mitral regurgitation (MR) poses a complex challenge. We recently validated an artificial intelligence-enabled electrocardiogram (AI-ECG) algorithm to detect LVDD and estimate LV filling pressures. Methods This retrospective study sought to examine the risk of all-cause mortality across AI-ECG LVDD grades. Patients from the AI-ECG LVDD study test cohort who underwent transthoracic echocardiography confirming significant MR and an ECG within fourteen days of each other at Mayo Clinic between 09/2001 and 06/2022 were included. LVDD status was determined based on the index ECG, and patients were categorized into groups representing normal diastolic function (NDF) or LVDD grades 1 (G1), 2 (G2), or 3 (G3). Results Of 4,019 patients with significant MR (mean age 69.8, 49.0% women), 1,175 (29.2%), 1,881 (46.8%), and 963 (24.0%) were classified by AI-ECG as NDF/G1-LVDD, G2-LVDD, and G3-LVDD, respectively. The median mitral effective regurgitant orifice area was 26 mm² (interquartile range 20-36 mm²). Over a median follow-up of 3.5 years, 1,636 (40.7%) patients died. In multivariable survival analysis adjusted for multiple risk factors, a worse AI-ECG LVDD grade was independently associated with an increased death risk [G2DD: adjusted hazard ratio (aHR) 1.98 (95% confidence interval (95% CI) 1.63-2.40), G3DD: aHR 2.59 (95% CI 2.09-3.20)]. These findings were consistent when accounting for mitral valve intervention and among patients with >moderate MR or after mitral valve intervention. Conclusion In patients with significant MR, the grading of LVDD by AI-ECG is independently associated with all-cause mortality.
Authors
- Sorin V. Pislaru (ORCID: https://orcid.org/0000-0002-5256-3150)
- Gal Tsaban (ORCID: https://orcid.org/0000-0003-4234-6504)
- Francisco López-Jiménez (ORCID: https://orcid.org/0000-0001-5788-9734)
- Garvan C. Kane (ORCID: https://orcid.org/0000-0002-4308-6356)
- Paul A. Friedman (ORCID: https://orcid.org/0000-0001-5052-2948)
- Abhishek Deshmukh (ORCID: https://orcid.org/0000-0002-9560-1102)
- Mehdi Abbasi (ORCID: https://orcid.org/0000-0001-6978-2563)
- Peter A. Noseworthy (ORCID: https://orcid.org/0000-0002-4308-0456)
- Zachi Itzhak Attia (ORCID: https://orcid.org/0000-0002-9706-7900)
- Samuel B. Wopperer
- S J Asirvatham
- Vuyisile T. Nkomo (ORCID: https://orcid.org/0000-0001-6095-5579)
- Hee Tae Yu (ORCID: https://orcid.org/0000-0002-6835-4759)
- Jae K. Oh (ORCID: https://orcid.org/0000-0002-8303-5780)
- Eunjung Lee (ORCID: https://orcid.org/0000-0001-9989-3555)
Institutions
- Mayo Clinic (US)
Publication Details
- Journal
- European Heart Journal
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1093/eurheartj/ehae666.1911
- Primary Topic
- Cardiac Imaging and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00